

## VitamFero moves into new laboratories for the industrial development of its veterinary vaccines

VitamFero is setting up its new facilities in the city of Angers, close to animal health industry leaders

Angers, France: November 6, 2017

**VitamFero**, a French veterinary biotech company specialized in creating and developing new prophylactic approaches, is announcing its relocation to a new site and will now have over 150 sq.m of L2 and L3 containment laboratories for the pharmaceutical development of its various vaccine candidates. The new building offers opportunities for further facilities to be set up, enabling the company to move forward with its industrial growth.

Close to the Amsler business incubator and the University Hospital Research Center, VitamFero will now be able to benefit from an ecosystem that is adapted for its activities, with access to imaging and bioanalysis platforms, as well as an animal housing facility. This outstanding environment is further strengthened by the presence of several animal health industry leaders including Ceva Animal Health, Merck Animal Health and Filavie (Grimaud group).

Didier Roy, Vice President Finance and Operations: *“Our move to Angers highlights the level of maturity achieved by VitamFero since its inception and gives us an identity aligned with our ambitious goal to secure the commercial launch of our first two products within the next three years. Thanks to the dynamic approach adopted by our landlord - Syndicat Mixte Angevin pour le Développement et l'Application de la Recherche (SADAR) and Angers Loire Développement (ALDEV) - we now are working in facilities that are perfectly adapted to our needs and we should be able to successfully meet the challenges that lie ahead”.*

---

### About VitamFero

VitamFero S.A. is a French biotech company specialized in immunotherapy for animal health. Its goal is to create, develop and sell new biologics to prevent infectious diseases among livestock and to reduce the use of antibiotics. Its patented technologies, such as Toxo KO and Neo KO, are based on non-virulent live vectors expressing genes coding for selected relevant proteins for vaccine development. This technological platform is also used to develop vaccines protecting animals from infections that are the most economically devastating for breeders and the most dreadful for their ability to mutate into human infectious strains. Through its participation in the veterinary segment of the “One Health” approach, which integrates animal, human, and environmental health, VitamFero affirms its commitment to public health. Find out more on [www.vitamfero.com](http://www.vitamfero.com)

### Contact

Calyptus - Mathieu Calleux - [vitamfero@calyptus.net](mailto:vitamfero@calyptus.net)  
VitamFero - Pascal Breton, Directeur Général - [p.breton@vitamfero.com](mailto:p.breton@vitamfero.com) - Tél. : +33 (0)6 82 65 47 69